Published Medical Literature

Efficacy of Chemotherapy Plus Checkpoint Inhibition in Metastatic Breast Cancer Under Study

Triple-Negative Breast Cancer: Mixed 19-Peptide Vaccine Monotherapy

Search for Optimal Dose of Nab-paclitaxel for Older Patients With Advanced Breast Cancer

Early Breast Cancer or DCIS: Hypofractionated Versus Standard-Fractionated Radiotherapy

Does Timing of Neoadjuvant Chemotherapy Affect Outcomes in Early-Stage Breast Cancer?

Opioid Use After Surgical Resection of Breast Cancer

Are Circadian Disruption and Breast Carcinogenesis Related?

CHK1 Inhibitor in BRCA Wild-Type Triple-Negative Breast Cancer

Music May Help Women in Chemotherapy for Breast Cancer

CLCA2 Expression: Prognostic Biomarker for Triple-Negative Breast Cancer in Black Women?

Lessons From NALA: Biomarkers of Treatment Response in Metastatic Breast Cancer

Does Exercise Improve Outcomes in Patients Treated for High-Risk Breast Cancer?

Patient-Reported Barriers to Discussing Sexual Concerns With Health-Care Providers

Quality of Life During Pembrolizumab Treatment for Metastatic Triple-Negative Breast Cancer

Subcutaneous Versus Intravenous Pertuzumab/Trastuzumab in Early Breast Cancer: Patient Perspective

Phase III Trial of Triplet Regimen for HER2-Positive Metastatic Breast Cancer

Combination of Abemaciclib, Pembrolizumab, and Anastrozole in Metastatic Breast Cancer

Ipatasertib Plus Paclitaxel in Triple-Negative Breast Cancer: Final Results of LOTUS Trial

Link Between Polypharmacy and Inpatient Hospitalization in Older Patients With Breast Cancer?

Identifying Cancer in Dense Breasts: Abbreviated MRI Versus 3D Mammography

Does Neoadjuvant Chemotherapy Streamline Breast Cancer Treatment?

Updated ASCO Guidelines on Male Breast Cancer: Different Approaches for Men and Women?

Assessment of Genetic Mutations in Postmenopausal Women With Breast Cancer

Cognitive Impairment in Women With Breast Cancer: Comparison of Adjuvant Therapies

Ductal Carcinoma in Situ: Link Between Estradiol/Testosterone Levels and Increased Risk?

Relationship Between Thyroid Dysfunction and Risk of Breast and Thyroid Cancers

CA 15-3 and Vitamin D: Prognostic Indicators in Patients Treated for Breast Cancer?

Breast Cancer and COVID-19: Alternative Radiation Therapies

Shortened Course of Radiotherapy for Breast Cancer: 5-Year Results From FAST-Forward Trial

Psychosocial Status and Geriatric Abnormalities in Metastatic Breast Cancer

PALB2-Associated Risks of Breast and Other Cancers

Got Milk? Study Finds Potential Link Between Dairy Intake and Breast Cancer

Germline Genetic Testing and Treatment Variation in Women With Breast Cancer

Preventive Tamoxifen Therapy: Are Women Aware of the Risks Along With the Benefits?

Does Extended Adjuvant Capecitabine Improve Survival in Triple-Negative Breast Cancer?

Should There Be an Upper Age Limit for Annual Screening Mammography?

Pathologic Complete Response With Pembrolizumab for Triple-Negative Breast Cancer

Heat Shock Protein 47 and Breast Cancer Metastasis

Risk of Ischemic Heart Disease After Radiotherapy for Breast Cancer

21-Gene Assay Recurrence Score in Predicting Locoregional Recurrence of Breast Cancer

Investigators Map Genetic Variants Linked to Breast Cancer

Second-Line Gemcitabine With Dual Antibody Therapy for ERBB2-Positive Metastatic Breast Cancer

AKT Inhibitor Plus Paclitaxel in Metastatic Triple-Negative Breast Cancer

Microflora and Breast Cancer: Are Some Bacteria Protective and Others Not?

Neoadjuvant Therapy and Eligibility for Breast Conservation in Triple-Negative Disease

Breast Cancer Screening: Personalizing Starting Age Based on Reproductive Factors

Ribociclib Plus Fulvestrant for Advanced Breast Cancer: Update From MONALEESA-3

Does Use of Dietary Supplements During Chemotherapy for Breast Cancer Improve Survival?

Does Treatment Delay Differentially Impact Overall Survival Across Breast Cancer Phenotypes?

Total Cumulative Dose of Chemotherapy and Breast Cancer Survival Rates

Metastatic Sites and Survival Outcomes Among Patients With Advanced Breast Cancer

Use of Supplemental MRI Screening in Women With Extremely Dense Breast Tissue

Proton Beam Radiotherapy for Nodal Irradiation in Patients With Breast Cancer

Update on Prognosis Patterns in Men With Breast Cancer

Breast Cancer Mortality Risk in Women With a History of Thyroid Cancer

GeparSepto Trial: Long-Term Results With Nab-paclitaxel in Early Breast Cancer

Stromal Tumor-Infiltrating Lymphocytes: Prognostic Indicator in Triple-Negative Breast Cancer?

Adjuvant Trastuzumab and Cardiac Toxicities in Patients With Breast Cancer

KATE2 Trial: Updated Overall Survival With Immunotherapy Combination in Advanced Breast Cancer

Machine Learning May Improve Accuracy of Breast Cancer Diagnoses

Update on CDK4/6 and Aromatase Inhibitors in Older Women With Breast Cancer

Is Sex a Contributing Factor to Mortality Disparity in Breast Cancer?

Is Breast Cancer Screening Effective in High-Risk Men?

Insurance and Mortality in Breast and Other Cancers

Final Results of MARIANNE Trial of T-DM1 in HER2-Positive Advanced Breast Cancer

Menopausal Hormone Replacement Therapy and Increased Risk of Breast Cancer

Niraparib Plus Pembrolizumab in Advanced Triple-Negative Breast Cancer

Learning More About Breast Cancer in Adolescents and Young Adults

Breast Cancer Screening in Women With Familial Risk: MRI or Mammography?

Timeliness of Chemotherapy Initiation After Breast Cancer Diagnosis and Survival

TAILORx Trial: Predicting Benefit From Chemotherapy in Early Breast Cancer

Adjuvant Trastuzumab for HER2-Positive Breast Cancer: Results of Two Phase III Trials

HannaH Trial: Subcutaneous Versus Intravenous Trastuzumab in Early Breast Cancer

Role of Lymphoscintigraphy in Sentinel Lymph Node Biopsy for Early Breast Cancer

Pain and Depression in Patients Treated for Breast Cancer

Parity-Associated Gene Expression and Breast Cancer in Premenopausal Women

How an Intervention Trial Addressed Racial Disparities in Treatment of Early-Stage Cancers

Targeting Triple-Negative Breast Cancer With Combination of PARP Inhibitors

Overall Survival With CDK4/6 Inhibitor in Hormone Receptor–Positive Breast Cancer

Niraparib Plus Pembrolizumab in Triple-Negative Breast Cancer: TOPACIO/KEYNOTE-162 Trial

Lifetime Incidence of Brain Metastasis in Elderly Survivors of Breast Cancer

Long-Term Outcomes With Adjuvant Paclitaxel and Trastuzumab in HER2-Positive Breast Cancer

Eribulin Versus Vinorelbine in Locally Recurrent or Metastatic Breast Cancer

Does Primary Care Appointment Time Affect Breast Cancer Screening Rates?

Chronic Opioid Use in Breast Cancer Survivors

Potential Prognostic Marker Identified for Triple Negative Breast Cancer

Genetic Testing in Patients With Breast and Ovarian Cancers

Preoperative Breast MRI and Surgical Outcomes in Local Ductal Carcinoma in Situ

Linking Pregnancy and the Genomic Landscape of Subsequent Breast Cancer

Breast Cancer Risk in Women With BRCA Mutations: Role of Number of Pregnancies

Addition of First-Line Fulvestrant to Anastrozole in Metastatic Breast Cancer

Long-Term Follow-up of Adjuvant Tamoxifen in Women With Breast Cancer

KAMILLA Trial: T-DM1 Safety in HER2-Positive Breast Cancer

Complications After Immediate Implant-Based Breast Cancer Reconstruction

Can Celecoxib Be Used to Treat HER2-Negative Breast Cancer?

Ovarian Function Suppression in Women With Breast Cancer: Degarelix Versus Triptorelin

Extended Letrozole Therapy After Aromatase Inhibitor–Based Therapy in Breast Cancer

Survival Outcomes With Palbociclib and Fulvestrant in Breast Cancer

Addition of Palbociclib to Letrozole in Estrogen Receptor–Positive Breast Cancer

Is There a Link Between Childbirth and Breast Cancer Risk?

Anthracycline Use in Neoadjuvant Therapy for HER2-Positive Breast Cancer

Axillary Radiotherapy as an Alternative to Axillary Lymph Node Dissection for Early Breast Cancer

Cosmetic Outcomes With Irradiation in Stages 0 to II Breast Cancer

Novel Statistical Approach Calculates Risk of Breast Cancer Recurrence in American Women

Extending Aromatase Inhibitor Therapy in Breast Cancer

Continued Benefit of Adding Goserelin to Chemotherapy in Women With Breast Cancer

Combination of Paclitaxel, Sorafenib, and Radiation in Advanced Breast Cancer

Lucitanib for Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

PALB2 Mutation in Hereditary Breast and Ovarian Cancer

How Accurate Are NCDB Comorbidity Assessments in Breast Cancer and Other Resected Tumors?

Racial Differences in Adherence to Endocrine Therapy for Breast Cancer

Update on Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors

Atezolizumab in Metastatic Triple-Negative Breast Cancer: Long-Term Outcomes

Population-Level Genomic Screening for Hereditary Breast Cancer

Alliance Study: Comparing Neoadjuvant Therapy Approaches in HER2-Positive Breast Cancer

Are Fertility-Related Hormone and Breast Cancer Development Linked?

Novel Tool to Predict Risk of Late Distant Recurrence in Patients With Breast Cancer

Update on Trends in Breast Cancer Survival Among Young Women

Impact of Screening on Breast Cancer Mortality Assessed in Danish Study

Can Circulating Tumor Cells Predict Late Recurrence in Breast Cancer?

Long-Term Safety Profile of Palbociclib With Endocrine Therapy

ASCO Clinical Practice Guidelines Updates in Advanced HER2-Positive Breast Cancer

Neoadjuvant Chemotherapy Plus Panitumumab in Inflammatory Breast Cancer

ASCO Guideline Update: Adjuvant Chemotherapy and Targeted Therapy for Breast Cancer

Fear and Worry Over Breast Cancer Among Women Facing Surgical Decisions

Comparing Trastuzumab Biosimilar and Reference Trastuzumab in HER2-Positive Breast Cancer

Update to ASCO/CAP Guidelines on HER2 Testing in Breast Cancer

Association of Prognosis in Early Breast Cancer With Somatic Driver Alterations

Safety of Pregnancy After Estrogen Receptor–Positive Breast Cancer

Clinical Relevance of Multigene Sequencing in Patients With Breast Cancer

Are Long-Term Survivors of Triple-Negative Breast Cancer Being Referred for Genetic Counseling?

Link Between CTC Status and Radiotherapy Benefit in Early-Stage Breast Cancer

Screening for Intracranial Disease in Patients With Metastatic Breast Cancer

Cardiovascular Risks Associated With Breast Cancer and Its Treatments

Are Patients Diagnosed With Breast Cancer Receiving Clinically Indicated Genetic Counseling?

Disparities in Genetic Testing for Hereditary Breast Cancer in the United States

Is Hormone Therapy a Risk Factor for Diabetes in Breast Cancer Survivors?

Novel Second-Line Treatment of Aromatase Inhibitor–Resistant Breast Cancer

Genetic Biomarker as Potential Predictor of Platinum Sensitivity in Triple-Negative Breast Cancer

Addition of Veliparib to Standard Neoadjuvant Therapy in Triple-Negative Breast Cancer

Predicting Risk of Breast Cancer: Automated Versus Clinical Assessment of Breast Density

Postmastectomy Radiation Therapy for Locoregional Control of Breast Cancer

CALOR Trial: Adjuvant Chemotherapy for Isolated Locoregional Recurrence of Breast Cancer

Use of Metronomic Chemotherapy in Older Patients With Metastatic Breast Cancer

Bone Turnover Markers in Metastatic Breast Cancer

Combination Therapy Under Study in Treatment-Resistant Breast Cancer

First-Degree Family History and Breast Cancer Risk in Women Older Than Age 65

Androgen Receptor–Targeted Treatment in Triple-Negative Breast Cancer

Distant and Locoregional Recurrence in Stage II or III Breast Cancer

Updated Results on Neratinib in HER2-Positive Breast Cancer

Correlation Between Breast Cancer Mortality and Advances in Screening and Treatment

Neoadjuvant Versus Adjuvant Chemotherapy in Early Breast Cancer

Dual HER2 Blockade in Metastatic Breast Cancer

Pertuzumab-Containing Neoadjuvant Regimens in HER2-Positive Breast Cancer

Dual HER2-Targeting Treatments for Postmenopausal Women With Metastatic Breast Cancer

Hormonal Birth Control and Invasive Breast Cancer Risk

Safety Profile of Buparlisib Plus Fulvestrant in Advanced Breast Cancer

Survival Benefit of Intense Dose-Dense Chemotherapy in High-Risk Breast Cancer

Use of Duloxetine for Arthralgias Associated With Breast Cancer Treatment

Letrozole Schedules Compared in Postmenopausal Women With Breast Cancer

Textured Breast Implants and Rare Anaplastic Lymphoma

Type 2 Diabetes and Breast Cancer Subtype in African American Women

Cardiac Effects of Trastuzumab Therapy in Patients With HER2-Positive Breast Cancer

Bacterial Imbalances and Breast Cancer

Initial Therapy With Abemaciclib for Advanced Breast Cancer

Effect of 5 Years’ Endocrine Therapy on Breast Cancer Recurrence

cT1–2N0 Breast Cancer: Less- and More-Invasive Treatment Results

Mortality in Elderly, Mentally Ill Breast Cancer Patients

Physicians’ Views on Radiotherapy for Older Women With Early-Stage Breast Cancer

Neoadjuvant Combination Therapy for HER2-Positive Primary Breast Cancer

HER2-Targeted Therapy and Breast Reconstruction

Soy Foods and Breast Cancer Survival

Surgeon Impact on the Decision to Have Contralateral Prophylactic Mastectomy

Investigational AKT Inhibitor in Triple-Negative Breast Cancer

Neoadjuvant Ado-trastuzumab Emtansine vs. Trastuzumab in Early Breast Cancer

Tamoxifen Metabolite Z-Endoxifen in Metastatic Breast Cancer

Current Treatment Approaches for Triple-Negative Breast Cancer

Response to Immunotherapy in Patients With ‘Claudin-Low’ Breast Tumors

Comparing Trastuzumab-Based Regimens in Older Women With Early-Stage Breast Cancer

Surveillance Mammography for Older Survivors of Breast Cancer

Wound Complications After Breast Reconstruction Procedures

Potential Toxicities Associated With CDK4/6 Inhibitors in Breast Cancer

Using Molecular Signature to Identify Indolent Breast Tumors

Oral Vinorelbine in Patients With Endocrine-Pretreated Breast Cancer

Changes in Histology and Breast Cancer Risk

MONARCH 2: Abemaciclib/Fulvestrant in Hormone Receptor–Positive, HER2-Negative Breast Cancer

Adding Pertuzumab to Trastuzumab and Chemotherapy in HER2-Positive Breast Cancer

Final Survival Data From TH3RESA Trial in Breast Cancer

Final Overall Survival Data From EMILIA Trial

Biologic Differences in Invasive Breast Cancers Among Black and White Patients

OlympiAD Trial: Olaparib in HER2-Negative Metastatic Breast Cancer

Additional Surgery After Initial Lumpectomy

Patient Satisfaction With Breast Reconstruction

More Women Living With Metastatic Breast Cancer

Combining Monoclonal Antibodies in HER2-Positive Breast Cancer

ABC Breast Cancer Trials of Adjuvant Taxane With or Without Anthracycline in HER2-Negative Disease

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

Optimizing Adherence to Oral Chemotherapy

Steadily Increasing Breast Cancer Rates in Asian Americans

Study Finds Discrepant Decision-Making for Use of 21-Gene Assay in Women With Early-Stage Breast Cancer

Bone Density Screening in Postmenopausal Women With Early-Stage Breast Cancer Treated With Aromatase Inhibitors

Contralateral Prophylactic Mastectomy Decisions in Patients With Early-Stage Breast Cancer

Identifying Educational Needs of the Multidisciplinary Cancer Team in the Treatment of Metastatic Breast Cancer

A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer

Improved Survival With Higher TIL Values in Advanced HER2-Positive Breast Cancer

A Review of Treatment for Breast Cancer–Related Lymphedema: Paradigms for Clinical Practice

Stereotactic Radiosurgery for Treatment of Brain Metastases